JE
Jenburkt Pharmaceuticals Ltd (JENBURPH)
₹915.25
Mkt cap
₹432 Cr
P/E ratio
12.10
P/B
2.05
Div yield
2.11%
ROE
20.20%
ROCE
27.00%
EPS (TTM)
₹75.64
Book value
₹446
52W range
34–1,074
Sector
Healthcare
Price history
Previous close
Incorporated in 1985, Jenburkt Pharmaceuticals Ltd manufactures and markets branded Pharmaceuticals and health care products [1]
NSE JENBURPHBSE 524731
Health check
Constructive
ValuationCheap
ProfitabilityStrong
GrowthModerate
TechnicalsNeutral
52-week range
−14.77% from high₹915
₹34+2,560.61% from low₹1,074
Current
₹915.25
Prev close
₹914.60
Day
+0.07%
Price performance
1D
−0.50%
1W
−4.61%
1M
−13.17%
3M
—
6M
—
1Y
—
YTD
−12.42%
Financials
Revenue, profit & margin
P/E ratio
12.1×
JENBURPH is 65% below the sector median of 34.6×
JENBURPH12.1×
Sector median34.6×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 29.18 | 38.29 | 35.66 | 38.84 | 32.54 | 41.22 | 36.89 | 41.05 | 35.53 | 45.56 | 43.02 | 44.63 | 35.51 | |
| Expenses | 22.22 | 29.19 | 28.47 | 28.99 | 23.26 | 29.79 | 28.07 | 30.19 | 26.58 | 32.45 | 35.59 | 30.38 | 29.48 | |
| Operating Profit | 6.96 | 9.10 | 7.19 | 9.85 | 9.28 | 11.43 | 8.82 | 10.86 | 8.95 | 13.11 | 7.43 | 14.25 | 6.03 | |
| OPM % | 23.85% | 23.77% | 20.16% | 25.36% | 28.52% | 27.73% | 23.91% | 26.46% | 25.19% | 28.78% | 17.27% | 31.93% | 16.98% | |
| Other Income | 1.04 | 1.10 | 1.35 | 1.19 | 1.41 | 1.85 | 1.58 | 1.88 | 2.06 | 2.08 | 1.82 | 0.40 | 1.51 | |
| Interest | 0.07 | 0.07 | 0.07 | 0.06 | 0.11 | 0.12 | 0.11 | 0.11 | 0.11 | 0.11 | 0.12 | 0.13 | 0.13 | |
| Depreciation | 0.50 | 0.59 | 0.63 | 0.62 | 0.52 | 0.64 | 0.78 | 0.79 | 0.72 | 0.74 | 0.83 | 0.81 | 0.64 | |
| Profit before tax | 7.43 | 9.54 | 7.84 | 10.36 | 10.06 | 12.52 | 9.51 | 11.84 | 10.18 | 14.34 | 8.30 | 13.71 | 6.77 | |
| Tax % | 27.73% | 23.27% | 31.12% | 23.94% | 26.34% | 23.32% | 31.65% | 27.87% | 23.48% | 29.08% | 28.55% | 20.86% | 13.00% | |
| Net Profit | 5.37 | 7.32 | 5.40 | 7.88 | 7.42 | 9.60 | 6.51 | 8.54 | 7.79 | 10.16 | 5.93 | 10.85 | 5.89 | |
| EPS in Rs | 12.17 | 16.59 | 12.24 | 17.86 | 16.81 | 21.75 | 14.75 | 19.35 | 17.65 | 23.02 | 13.44 | 24.58 | 13.35 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
No reaction history yet.
No quarterly filings ingested yet.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Jun 202646.62%Promoter
Promoters46.62%0.02
FIIs0.00%
DIIs0.12%
Public53.27%0.03
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,837.30 | 34.90 | 4,40,830 | 0.87% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| Divi's Lab. | ₹9,375.00 | 83.54 | 2,48,877 | 0.32% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,840.00 | 82.51 | 1,84,098 | 0.79% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| Zydus Lifesci. | ₹1,160.00 | 23.77 | 1,15,710 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Cipla | ₹1,394.50 | 31.48 | 1,12,656 | 0.93% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| Laurus Labs | ₹1,954.00 | 96.56 | 1,05,577 | 0.10% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| Aurobindo Pharma | ₹1,734.00 | 26.39 | 99,771 | 0.23% | 1,032 | +28.11% | 9,150 | +16.30% | 12.86% |
| Jenburkt Pharma | ₹979.90 | 12.10 | 432 | 2.11% | 6 | −24.39% | 36 | −0.06% | 26.95% |
| Median: 158 Co. | ₹433.90 | 34.56 | 2,205 | 0.08% | 13 | +29.57% | 164 | +18.57% | 14.96% |
Filings
Annual reports15
Credit ratings1
Announcements5
Announcement under Regulation 30 (LODR)-Change in Management 18 Sep - Vinay Bhatt, SVP-International Business, resigned effective 18 September 2026.Shareholder Meeting / Postal Ballot-Scrutinizer''s Report 4 Sep - 41st AGM resolutions passed; 207% dividend declared, Dilip H. Bhuta reappointed WTD and CFO.Announcement under Regulation 30 (LODR)-Change in Directorate 4 Sep - Shareholders approved Dilip H. Bhuta’s reappointment as Whole Time Director and CFO1 April 2027 to 31 March 2032.Proceedings Of The 41St Annual General Meeting Of The Company Held On Friday, 04Th September, 2026. 4 Sep - Jenburkt Pharmaceuticals held its 41st AGM on 4 Sept 2026, approved ₹20.70 dividend and reappointed Dilip H. Bhuta.Shareholder Meeting / Postal Ballot-Outcome of AGM 4 Sep - Jenburkt Pharmaceuticals held its 41st AGM on 4 September 2026; dividend ₹20.70 per share proposed.